BEAM
Price
$17.14
Change
+$0.38 (+2.27%)
Updated
Jun 26 closing price
Capitalization
1.72B
46 days until earnings call
GYRE
Price
$7.38
Change
-$0.03 (-0.40%)
Updated
Jun 26 closing price
Capitalization
666.59M
53 days until earnings call
Interact to see
Advertisement

BEAM vs GYRE

Header iconBEAM vs GYRE Comparison
Open Charts BEAM vs GYREBanner chart's image
Beam Therapeutics
Price$17.14
Change+$0.38 (+2.27%)
Volume$1.3M
Capitalization1.72B
Gyre Therapeutics
Price$7.38
Change-$0.03 (-0.40%)
Volume$209.91K
Capitalization666.59M
BEAM vs GYRE Comparison Chart in %
Loading...
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BEAM vs. GYRE commentary
Jun 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEAM is a Buy and GYRE is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 27, 2025
Stock price -- (BEAM: $17.14 vs. GYRE: $7.38)
Brand notoriety: BEAM and GYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BEAM: 72% vs. GYRE: 87%
Market capitalization -- BEAM: $1.72B vs. GYRE: $666.59M
BEAM [@Biotechnology] is valued at $1.72B. GYRE’s [@Biotechnology] market capitalization is $666.59M. The market cap for tickers in the [@Biotechnology] industry ranges from $301.01B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BEAM’s FA Score shows that 1 FA rating(s) are green whileGYRE’s FA Score has 1 green FA rating(s).

  • BEAM’s FA Score: 1 green, 4 red.
  • GYRE’s FA Score: 1 green, 4 red.
According to our system of comparison, GYRE is a better buy in the long-term than BEAM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BEAM’s TA Score shows that 3 TA indicator(s) are bullish while GYRE’s TA Score has 3 bullish TA indicator(s).

  • BEAM’s TA Score: 3 bullish, 5 bearish.
  • GYRE’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, BEAM is a better buy in the short-term than GYRE.

Price Growth

BEAM (@Biotechnology) experienced а +0.88% price change this week, while GYRE (@Biotechnology) price change was -11.40% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.59%. For the same industry, the average monthly price growth was +34.25%, and the average quarterly price growth was +14.95%.

Reported Earning Dates

BEAM is expected to report earnings on Aug 12, 2025.

GYRE is expected to report earnings on Aug 19, 2025.

Industries' Descriptions

@Biotechnology (+3.59% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BEAM($1.72B) has a higher market cap than GYRE($667M). BEAM YTD gains are higher at: -30.887 vs. GYRE (-39.008). GYRE has higher annual earnings (EBITDA): 12.1M vs. BEAM (-399.03M). BEAM has more cash in the bank: 1.22B vs. GYRE (29.9M). GYRE has less debt than BEAM: GYRE (1.59M) vs BEAM (158M). GYRE has higher revenues than BEAM: GYRE (101M) vs BEAM (63.6M).
BEAMGYREBEAM / GYRE
Capitalization1.72B667M258%
EBITDA-399.03M12.1M-3,298%
Gain YTD-30.887-39.00879%
P/E RatioN/A369.00-
Revenue63.6M101M63%
Total Cash1.22B29.9M4,080%
Total Debt158M1.59M9,968%
FUNDAMENTALS RATINGS
GYRE: Fundamental Ratings
GYRE
OUTLOOK RATING
1..100
74
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
63
PRICE GROWTH RATING
1..100
88
P/E GROWTH RATING
1..100
8
SEASONALITY SCORE
1..100
19

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
BEAMGYRE
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
78%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
82%
MACD
ODDS (%)
Bullish Trend 1 day ago
89%
Bearish Trend 1 day ago
80%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
86%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
86%
Advances
ODDS (%)
Bullish Trend 10 days ago
78%
Bullish Trend 10 days ago
81%
Declines
ODDS (%)
Bearish Trend 5 days ago
85%
Bearish Trend 1 day ago
84%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
84%
Bullish Trend 1 day ago
76%
Aroon
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
REGRX18.630.13
+0.70%
Russell Inv Emerging Markets R6
FLRYX41.66N/A
N/A
Nuveen Large Cap Select I
MIGBX32.31N/A
N/A
MFS Massachusetts Inv Gr Stk B
TLGCX9.12N/A
N/A
Timothy Plan Large/Mid Cap Growth C
VKSRX20.17N/A
N/A
Virtus KAR Small-Mid Cap Core R6

BEAM and

Correlation & Price change

A.I.dvisor indicates that over the last year, BEAM has been closely correlated with CRSP. These tickers have moved in lockstep 72% of the time. This A.I.-generated data suggests there is a high statistical probability that if BEAM jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BEAM
1D Price
Change %
BEAM100%
+2.27%
CRSP - BEAM
72%
Closely correlated
-0.17%
RXRX - BEAM
64%
Loosely correlated
+4.65%
NTLA - BEAM
64%
Loosely correlated
+0.52%
SYRE - BEAM
58%
Loosely correlated
+3.96%
ABSI - BEAM
58%
Loosely correlated
-1.81%
More